Last reviewed · How we verify
A1
A1 works by inhibiting the action of a specific enzyme.
A1 works by inhibiting the action of a specific enzyme. Used for Type 2 diabetes.
At a glance
| Generic name | A1 |
|---|---|
| Also known as | Celixir 20 T1/C20- CBD 20%, THC 1%, Placebo |
| Sponsor | Breath of Life International Pharma Ltd |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
A1 specifically targets and inhibits the activity of this enzyme, leading to a cascade of downstream effects that ultimately result in therapeutic benefits.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- Immediate Restoration of a New Implant With High Primary Stability (NA)
- A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer (NA)
- Closed Versus Open Lateral Internal Sphincterotomy for Chronic Anal Fissure (NA)
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Effect of Local Application of 1% Metformin Gel on Implant Stability and Peri-implant Bone Density: A Randomized Controlled Study (NA)
- A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (PHASE3)
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia (PHASE1)
- ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A1 CI brief — competitive landscape report
- A1 updates RSS · CI watch RSS
- Breath of Life International Pharma Ltd portfolio CI